Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy – guidance (TA692)

Pembrolizumab is not recommended for locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. The most plausible cost‑effectiveness estimate were higher than what NICE normally considers acceptable for end‑of‑life treatments.

Source:

National Institute for Health and Care Excellence